On November 2, I outlined several financing scenarios. We now have scenario 3, and as predicted "Share price resets to mid to high $ 2's based on the dual negatives of dilution and the manifest inability of management to secure funded partnerships". The immediate pressure is off to secure badly needed near term financing, albeit achieved in a way dilutive to shareholders. The next question that will determine the real opportunity for the company is the ability to secure several partnerships, in Q-1 2013, that will add longer term financing, provide for broader distribution, and a offer a potential exit strategy through M&A. Equally importantly is executing on clinical and commercial milestones. If these twin objectives are achieved the valuations outlined in scenario 1"Stock pops to high $ 4's/low $ 5's. Additional share appreciation dependent on achieving 2013 clinical milestones. If accomplished stock can organically reach $ 10 by YE 2013. Attaining these milestones will likely attract acquisition interest from several Big Pharma's, a 30%+ purchase premium to then current share price is reasonable.
I wonder if the potential partners look at the story telling verbal that flows from the mouths of these guys and wonders"DO I WANNA DO BUSINESS WITH THESE PEOPLE" I realize for some it's all about the money but you might want to reconsider your position when doing business with sharks,